Dr Martens Plc shares experienced a significant increase of up to 21% during early trading in London after reporting a stronger-than-expected performance for the first half of the year.
The company's sales for the six months ending September 29 reached £324.6 million ($410.7 million), surpassing analyst predictions of £318.7 million.
This positive outcome is particularly significant for Dr Martens, as its shares have declined by approximately 26% so far this year, mainly due to concerns about demand in the US market.
Despite these challenges, the company remains on track to achieve the targets it set earlier in the year, indicating potential signs of recovery in its key markets.